Business Overview
RCM Technologies, Inc. (NasdaqGM: RCMT) operates as a premier provider of business and technology solutions, utilizing its talent base across key market segments to enhance the operational performance of its clients. The Company’s core mission is centered on helping to design, build, and enable the “Industries of Tomorrow, Today”. Strategically operating at the intersection of resources, critical infrastructure, and industrial modernization, RCM provides specialized services across multiple domains. These domains encompass Healthcare, Engineering, Aerospace & Defense, Process & Industrial, Life Sciences, and Data & Solutions. The Company deploys advanced engineering, specialty healthcare, and information technology services to address its customers’ operational requirements.
Key Financial Performance Highlights
Fourth Quarter 2025
For the current quarter, which consisted of fourteen weeks, RCM Technologies reported total revenue of $86.476 million. This represents an increase of 12.4% compared to the $76.912 million reported during the thirteen weeks ended December 28, 2024 (the comparable prior quarter). Cost of services for the quarter scaled to $62.198 million from $55.343 million in the prior year. Consequently, gross profit stood at $24.278 million, demonstrating a 12.6% year-over-year increase from $21.569 million in the comparable prior quarter.
Operating income for the quarter improved materially to $7.971 million, up from $6.285 million in Q4 2024. The Company experienced a reduction in income tax expense, which fell to $1.087 million from $2.902 million in the comparable period. This culminated in a GAAP net income of $6.104 million, or $0.80 per diluted share, a substantial increase compared with $2.867 million, or $0.37 per diluted share, in the prior year’s quarter. The diluted weighted average shares outstanding decreased to 7,587,448 from 7,733,142 in the comparable quarter.
Fiscal Year 2025
For the current fiscal year (fifty-three weeks), the Company generated total revenue of $319.404 million. This marks a 14.7% increase over the $278.380 million generated in the fifty-two weeks ended December 28, 2024. Cost of services for the year was $231.461 million compared to $198.602 million in the prior year. Gross profit for the year reached $87.943 million, reflecting a 10.2% increase from the $79.778 million reported in the preceding year.
Selling, general, and administrative (SG&A) expenses increased to $60.932 million from $56.787 million in FY 2024. The Company’s consolidated operating income for the year was $25.093 million, up from $22.325 million. GAAP net income for the fiscal year aggregated to $16.334 million, or $2.14 per diluted share, compared to $13.327 million, or $1.68 per diluted share, during the comparable prior year. The diluted weighted average shares outstanding for the year were 7,635,740, down from 7,939,381 in FY 2024.
Segment-Wise Performance Analysis
RCM Technologies segments its operational reporting into three distinct categories: Specialty Health Care; Engineering; and Life Sciences, Data and Solutions.
Specialty Health Care
- Q4 2025: Revenue was $47.999 million, up from $41.011 million in Q4 2024. Gross profit for the segment reached $13.932 million compared to $12.537 million in the prior year’s quarter. However, the gross profit margin contracted to 29.0% from 30.6% in Q4 2024.
- FY 2025: Revenue increased to $164.104 million from $142.679 million in FY 2024. Gross profit grew to $47.402 million from $42.533 million, while the gross profit margin experienced a slight compression to 28.9% from 29.8% in the preceding year.
Engineering
- Q4 2025: The segment generated $30.404 million in revenue, compared to $26.279 million in Q4 2024. Gross profit expanded significantly to $7.796 million from $5.181 million. Furthermore, the segment’s gross profit margin improved dramatically by 590 basis points, reaching 25.6% compared to 19.7% in the prior year’s quarter.
- FY 2025: Revenue totaled $120.486 million, up from $96.459 million in the prior year. Gross profit grew to $27.382 million from $22.543 million, though the gross profit margin declined slightly to 22.7% from 23.4% year-over-year.
Life Sciences, Data and Solutions
- Q4 2025: Revenue declined to $8.073 million from $9.622 million in Q4 2024. Gross profit decreased proportionally to $2.550 million from $3.851 million, resulting in a margin compression to 31.6% from 40.0% in the comparable prior quarter.
- FY 2025: Revenue contracted to $34.814 million from $39.242 million in FY 2024. Gross profit fell to $13.159 million from $14.702 million, but the gross profit margin expanded slightly to 37.8% from 37.5% year-over-year.
Operational Metrics and Key Drivers
The Company relies heavily on non-GAAP financial measures to supplement its GAAP reporting, specifically highlighting Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income, and Adjusted diluted net earnings per share.
- Adjusted EBITDA: For the current quarter, Adjusted EBITDA increased by 49.0% to $9.318 million, compared to $6.254 million in the comparable prior quarter. For the fiscal year, Adjusted EBITDA rose by 18.9% to $30.743 million, up from $25.855 million in FY 2024.
- Adjusted Net Income Per Diluted Share: The Company reported $0.77 for the current quarter compared to $0.49 in the prior quarter. On an annual basis, this metric increased to $2.50 per share from $2.03 per share in the comparable prior year.
Key Adjustments to Non-GAAP Metrics: Several adjustments bridged the gap between GAAP operating income and Adjusted operating income. Notably, the Company recorded a favorable remeasurement of contingent consideration amounting to ($1.759) million in both Q4 2025 and FY 2025. Adjustments for equity compensation were $0.793 million for Q4 2025 (vs. $0.710 million in Q4 2024) and $3.732 million for FY 2025 (vs. $2.864 million in FY 2024). The Company also recorded an impairment of intangible assets amounting to $0.547 million in the current quarter and fiscal year.
For the calculation of Adjusted net income, a tax impact from a normalized rate was applied, utilizing an estimated effective income tax rate of 27.0% for both periods presented. This rate approximates the Company’s federal USA income tax rate plus the tax-affected rate for states and Puerto Rico. The specific tax impact adjustment from the normalized rate was ($1.068) million for Q4 2025 and ($1.324) million for FY 2025.
Balance Sheet and Liquidity Analysis
A review of the Condensed Consolidated Balance Sheets provides insight into the Company’s capitalization and working capital position at year-end.
- Assets: Total assets increased to $134.397 million as of January 3, 2026, from $132.077 million at December 28, 2024. Cash and cash equivalents decreased from $4.729 million to $2.922 million. Accounts receivable (net of provision for credit losses) grew to $81.243 million from $77.960 million. The provision for credit losses decreased to $1.229 million from $1.570 million.
- Liabilities: Total liabilities decreased substantially to $88.423 million from $98.593 million. This reduction was largely driven by a significant decrease in borrowings under the line of credit, which fell to $24.673 million from $34.967 million in the prior year. Current liabilities remained relatively stable at $53.884 million, compared to $53.633 million at the end of FY 2024. Accounts payable and accrued expenses decreased to $9.649 million from $13.369 million, and transit accounts payable decreased to $16.247 million from $23.870 million. Deferred revenue in current liabilities grew to $14.761 million from $4.163 million.
- Stockholders’ Equity: Total stockholders’ equity improved to $45.974 million from $33.484 million. This was supported by an increase in retained earnings, though accumulated deficit expanded to ($84.752) million from ($77.393) million. The Company also increased its holdings of treasury stock, which rose to 10,652,841 shares at the end of FY 2025, compared to 10,236,259 shares at the end of FY 2024, indicating share repurchase activity during the year.
Cash Flow Dynamics: Cash flow operations exhibited variability. For Q4 2025, net cash provided by operating activities was $11.445 million, a strong reversal from the net cash used in operating activities of ($1.637) million in Q4 2024. However, on a full-year basis, net cash provided by operating activities declined to $6.170 million in FY 2025, down from $18.965 million in FY 2024. Net cash used in investing activities for FY 2025 was $2.572 million, compared to $1.595 million in the prior year. Net cash used in financing activities for FY 2025 was $4.828 million, representing a steep reduction from the $19.038 million used in FY 2024. Overall, cash and cash equivalents decreased by ($1.807) million over the course of the fiscal year.
Management Commentary and Strategic Updates
Management explicitly stated that the non-GAAP financial measures provided are intended as useful information for investors, shareholders, and stakeholders to gauge operational results on an ongoing basis and enhance the understanding of current financial performance and period-to-period comparisons. Management cautions that these metrics should not be considered alternatives to GAAP operating income or net income as performance indicators, nor do they account for changes in assets, liabilities, interest, or income taxes that affect cash flows. The Company emphasized that these measures should only be read in conjunction with the GAAP consolidated financial statements.
Strategically, RCM Technologies opted not to hold a conference call to discuss these quarterly and fiscal year results. Investors seeking additional information are directed by management to consult the Company’s Form 10-K.
Notable Risks and Challenges
The Company’s earnings release includes comprehensive forward-looking statement disclosures, highlighting several inherent risks and uncertainties. Management notes that expectations regarding future revenues, financial results, cash flows, pipeline developments, potential project wins, and business growth investments are subject to variables that could cause actual events to differ materially.
These projections are based on assumptions formed by management’s experience, historical trend perceptions, and expectations of future developments. The Company explicitly directs investors to consider the specific risks, uncertainties, and other factors detailed in its filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. RCM Technologies disclaims any obligation to update its forward-looking statements in response to new information or future events, except where required by law.